Sandoz launches Europe's first ustekinumab biosimilar, Pyzchiva, for chronic inflammatory diseases.
Sandoz, a major player in generic and biosimilar medicines, has launched Pyzchiva (ustekinumab), a biosimilar for chronic inflammatory diseases across Europe. Developed by Samsung Bioepis, Pyzchiva is the first ustekinumab biosimilar with all reference medicine strengths, including 130mg vial initiation dose for Crohn's disease. The launch expands Sandoz's immunology portfolio and complements its five other biosimilars in Europe.
July 24, 2024
5 Articles